Daher Ayham, Müller Tobias, Spiesshoefer Jens, Dreher Michael, Panse Jens
Department of Pneumology and Intensive Care Medicine, University Hospital RWTH, Aachen, Germany.
Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH, Aachen, Germany.
Respir Med Case Rep. 2021;34:101560. doi: 10.1016/j.rmcr.2021.101560. Epub 2021 Nov 29.
A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did not improve despite dexamethasone and antibiotic therapy. After administration of bamlanivimab, a monoclonal antibody with high affinity for the receptor-binding domain of the SARS-CoV-2 spike protein, inflammatory markers rapidly decreased, SARS-CoV2 RT-PCR became negative, and the patient improved clinically and radiologically. In conclusion, we demonstrated successful treatment of prolonged COVID-19 in a patient with severe B-cell aplasia with a virus-neutralizing monoclonal antibody.
一名因接受抗CD20单克隆抗体治疗而出现B细胞耗竭的71岁女性患者因COVID-19病情恶化入院。总体而言，她持续出现病毒脱落，呼吸衰竭加重，尽管接受了地塞米松和抗生素治疗，但进行性肺炎仍未改善。给予巴姆兰尼单抗（一种对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白受体结合域具有高亲和力的单克隆抗体）后，炎症标志物迅速下降，SARS-CoV-2逆转录聚合酶链反应（RT-PCR）转为阴性，患者的临床症状和影像学表现均有所改善。总之，我们证明了用一种病毒中和单克隆抗体成功治疗了一名患有严重B细胞发育不全的长期COVID-19患者。
